BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haluzík M, Mráz M, Svačina Š. Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects. Drug Saf 2014;37:1003-10. [PMID: 25391858 DOI: 10.1007/s40264-014-0238-8] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
Number Citing Articles
1 Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones 2018;17:333-50. [DOI: 10.1007/s42000-018-0038-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
2 Pelantová H, Bugáňová M, Holubová M, Šedivá B, Zemenová J, Sýkora D, Kaválková P, Haluzík M, Železná B, Maletínská L, Kuneš J, Kuzma M. Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. Mol Cell Endocrinol 2016;431:88-100. [PMID: 27164444 DOI: 10.1016/j.mce.2016.05.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
3 Roca-Rodríguez MM, Muros de Fuentes MT, Piédrola-Maroto G, Quesada-Charneco M, Maraver-Selfa S, Tinahones FJ, Mancha-Doblas I. [Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control]. Aten Primaria 2017;49:294-9. [PMID: 27667144 DOI: 10.1016/j.aprim.2016.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 [PMID: 28031776 DOI: 10.4239/wjd.v7.i20.572] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
5 Pankova A, Kralikova E, Kavalkova P, Stepankova L, Zvolska K, Haluzik M. No Change in Serum Incretins Levels but Rise of Leptin Levels After Smoking Cessation: a Pilot Study. Physiol Res. [DOI: 10.33549/physiolres.933154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
6 Roca-Rodríguez Mdel M, Tapia-Guerrero MJ, Maraver-Selfa S, Tinahones FJ, Mancha-Doblas I. Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga. Endocrinol Nutr 2015;62:512-4. [PMID: 26423184 DOI: 10.1016/j.endonu.2015.07.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Lafferty RA, Tanday N, Flatt PR, Irwin N. Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity. Metabolism 2020;111:154339. [PMID: 32777442 DOI: 10.1016/j.metabol.2020.154339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wang J, Huang Y, Li K, Chen Y, Vanegas D, McLamore ES, Shen Y. Leaf Extract from Lithocarpus polystachyus Rehd. Promote Glycogen Synthesis in T2DM Mice. PLoS One 2016;11:e0166557. [PMID: 27893760 DOI: 10.1371/journal.pone.0166557] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]